EuBiologics유바이오로직스
206650 · KOSDAQ · ₩206650 · 유바이오로직스
₩7,460▲ ₩130 (1.77%)End-of-day · Oct 26, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩149B | ₩96B | ₩69B | ₩55B | ₩39B |
| Cost of sales | ₩63B | ₩40B | ₩35B | ₩31B | ₩24B |
| Gross profit | ₩86B | ₩56B | ₩33B | ₩25B | ₩15B |
| Operating income | ₩61B | ₩34B | ₩8.8B | −₩1.7B | −₩7.4B |
| Net income | ₩41B | ₩19B | −₩13B | −₩2.3B | −₩32B |
| Net income to shareholders | ₩41B | ₩19B | −₩13B | −₩2.3B | −₩32B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩240B | ₩202B | ₩152B | ₩161B | ₩149B |
| Current assets | ₩137B | ₩83B | ₩42B | ₩41B | ₩51B |
| Cash and equivalents | ₩24B | ₩23B | ₩9.9B | ₩11B | ₩4B |
| Total liabilities | ₩65B | ₩70B | ₩46B | ₩42B | ₩33B |
| Current liabilities | ₩42B | ₩43B | ₩25B | ₩24B | ₩17B |
| Borrowings | ₩0 | ₩8.5B | ₩12B | ₩13B | ₩13B |
| Total equity | ₩175B | ₩132B | ₩106B | ₩119B | ₩115B |
| Shareholders' equity | ₩175B | ₩132B | ₩106B | ₩119B | ₩115B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩49B | ₩43B | ₩27B | ₩8B | −₩6.6B |
| Capital spending | ₩5.5B | −₩5.8B | −₩6.9B | −₩9B | −₩6.6B |
| Free cash flow | ₩44B | ₩37B | ₩20B | −₩1B | −₩13B |
Consolidated where available. Amounts in won.
Also known as: EuBiologics / 유바이오로직스 / 206650 / KRX:206650
Source: KRX statistical information